Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SXTPW

60 Degrees Pharmaceuticals (SXTPW)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTPW
DateTimeSourceHeadlineSymbolCompany
07/02/202508:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
07/02/202506:07GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
07/02/202502:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/02/202501:22GlobeNewswire Inc.60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
31/01/202509:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
31/01/202506:20GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
31/01/202500:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
30/01/202500:00GlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
29/01/202508:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
29/01/202500:01GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
25/01/202508:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
25/01/202508:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/01/202509:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/01/202508:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
09/01/202508:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
09/01/202500:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
24/12/202400:57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
19/12/202412:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/12/202400:56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
10/12/202409:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
22/11/202410:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
15/11/202406:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
15/11/202405:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
07/11/202409:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
16/10/202406:46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
08/10/202423:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
03/10/202423:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
03/10/202400:56Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/10/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
20/09/202406:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTPW